Eventide Asset Management’s Immune Design Corp. IMDZ Stock Holding History

Eventide Asset Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-180,000	Closed	-$1.36M	–	136
2016 Q3	$1.36M	Hold	180,000	–	–	0.08%	101
2016 Q2	$1.47M	Hold	180,000	–	–	0.09%	101
2016 Q1	$2.34M	Hold	180,000	–	–	0.13%	98
2015 Q4	$3.61M	Buy	180,000 +25,499	+17%	+$439K	0.18%	97
2015 Q3	$1.89M	Buy	154,501 +51,597	+50%	+$967K	0.11%	100
2015 Q2	$2.13M	Buy	102,904 +20,947	+26%	+$495K	0.12%	97
2015 Q1	$1.73M	Buy	+81,957	New	+$2.14M	0.13%	98

Other funds holding IMDZ

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eventide Asset Management's IMDZ Position: Q4 2016 in Review

Eventide Asset Management sold out of Immune Design Corp. (IMDZ) in Q4 2016, closing a stake of 180,000 shares — an estimated $1.36M sold.

Eventide Asset Management first reported a position in IMDZ in Q1 2015 and held it in 7 quarters. The position peaked at $3.61M in Q4 2015. 65 funds tracked by Wall St. Rank hold IMDZ as of Q4 2016.

Eventide Asset Management reported no remaining Immune Design Corp. position as of Q4 2016 after selling out during the quarter.
Eventide Asset Management sold 180,000 Immune Design Corp. shares in Q4 2016, an estimated $1.36M.
Eventide Asset Management first reported a position in Immune Design Corp. in Q1 2015 and held it in 7 quarters.
Eventide Asset Management's Immune Design Corp. position peaked at $3.61M in Q4 2015.
65 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2016.

Based on Eventide Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.